Phantomics announced that it received the Best Innovation Technology Award at the FIX 2024 Innovation Awards.
The FIX Innovation Awards recognize products with outstanding innovation, technological excellence, and market potential among innovative technologies worldwide. Established this year, the awards aim to discover, nurture, and support companies with breakthrough technologies while solidifying industry-specific development strategies to enhance competitiveness in emerging industries.
The Best Innovation Technology Award is presented to eight top companies in various categories. Phantomics was named the leading company in the ABB (AI, Big Data, Blockchain) category. Its integration of AI with non-invasive diagnostic imaging technologies like MRI and CT to provide fast and accurate diagnostic results earned the company this prestigious recognition.
Phantomics’ flagship solution, Myomics, leverages AI to automatically analyze and quantify cardiac MRI images, enabling safe and accurate diagnosis of suspected myocardial diseases such as heart failure, myocarditis, and amyloidosis. The technology reduces image analysis time from 30 minutes to under 2 minutes, standardizes analyses to minimize inter-hospital variability, and provides accuracy comparable to tissue biopsies.
Pan Ki Kim, Co-CEO of Phantomics, expressed pride in the company’s achievement, saying, “Winning the inaugural FIX Innovation Awards is a tremendous honor for Phantomics. Following our CES 2024 Innovation Award earlier this year, receiving the Best Innovation Technology Award at FIX 2024 further demonstrates our innovation and technological excellence on both domestic and international stages. We will continue to develop cutting-edge AI solutions to enable early diagnosis and effective treatment of cardiovascular diseases, the world’s leading cause of death.”
Phantomics, a startup founded by faculty at Yonsei University Severance Hospital, is dedicated to overcoming cardiovascular diseases by combining non-invasive diagnostic imaging with AI to deliver fast and precise medical solutions. Its leading technologies include Myomics, an AI-based cardiac MRI solution, and Angiomics, a cardiac CT solution.
Myomics has gained recognition for its value in assisting medical professionals in treating patients promptly. It is currently used in over 20 major hospitals in Korea and in countries such as Japan, Taiwan, and Singapore. Earlier this year, Phantomics became the first company in the Korean medical imaging AI sector to win a CES Innovation Award in 2024 for its advanced technology and innovation.
The FIX 2024 (Future Innovation Tech EXPO), held from January 23 to 26, showcases cutting-edge technologies in future mobility, robotics, AI, semiconductors, and more. The event provides a platform to explore the latest advancements shaping the future of innovation.
Read Article
Phantomics announced that it received the Best Innovation Technology Award at the FIX 2024 Innovation Awards.
The FIX Innovation Awards recognize products with outstanding innovation, technological excellence, and market potential among innovative technologies worldwide. Established this year, the awards aim to discover, nurture, and support companies with breakthrough technologies while solidifying industry-specific development strategies to enhance competitiveness in emerging industries.
The Best Innovation Technology Award is presented to eight top companies in various categories. Phantomics was named the leading company in the ABB (AI, Big Data, Blockchain) category. Its integration of AI with non-invasive diagnostic imaging technologies like MRI and CT to provide fast and accurate diagnostic results earned the company this prestigious recognition.
Phantomics’ flagship solution, Myomics, leverages AI to automatically analyze and quantify cardiac MRI images, enabling safe and accurate diagnosis of suspected myocardial diseases such as heart failure, myocarditis, and amyloidosis. The technology reduces image analysis time from 30 minutes to under 2 minutes, standardizes analyses to minimize inter-hospital variability, and provides accuracy comparable to tissue biopsies.
Pan Ki Kim, Co-CEO of Phantomics, expressed pride in the company’s achievement, saying, “Winning the inaugural FIX Innovation Awards is a tremendous honor for Phantomics. Following our CES 2024 Innovation Award earlier this year, receiving the Best Innovation Technology Award at FIX 2024 further demonstrates our innovation and technological excellence on both domestic and international stages. We will continue to develop cutting-edge AI solutions to enable early diagnosis and effective treatment of cardiovascular diseases, the world’s leading cause of death.”
Phantomics, a startup founded by faculty at Yonsei University Severance Hospital, is dedicated to overcoming cardiovascular diseases by combining non-invasive diagnostic imaging with AI to deliver fast and precise medical solutions. Its leading technologies include Myomics, an AI-based cardiac MRI solution, and Angiomics, a cardiac CT solution.
Myomics has gained recognition for its value in assisting medical professionals in treating patients promptly. It is currently used in over 20 major hospitals in Korea and in countries such as Japan, Taiwan, and Singapore. Earlier this year, Phantomics became the first company in the Korean medical imaging AI sector to win a CES Innovation Award in 2024 for its advanced technology and innovation.
The FIX 2024 (Future Innovation Tech EXPO), held from January 23 to 26, showcases cutting-edge technologies in future mobility, robotics, AI, semiconductors, and more. The event provides a platform to explore the latest advancements shaping the future of innovation.
Read Article